Zhou C, Huang D, Fan Y, Yu X, et al. Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial. J Thorac Oncol 2022 Sep 29. pii: S1556-0864(22)01803.
PMID: 36184068